Mutants of canine interferon CaIFN-lambda and application thereof

• Main Authors: QIN TONG, CUI SHANGJIN
• Format: Patent
• Language: Chinese; English
• Published: 05.06.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention discloses a group of recombinant canine interferon CaIFN-lambda proteins, namely mutant proteins of wild type canine interferon CaIFN-lambda proteins. The biological activity of three interferon CaIFN-lambda mutants in the group of mutant proteins is remarkably superior to the biological activity of wild type canine interferon CaIFN-lambda. The recombinant wild canine interferon CaIFN-lambda proteins provided by the invention has excellent antiviral activity, and has huge potential and value in development into antiviral drugs and in veterinary clinical application. 本发明公开了一组重组犬干扰素CaIFN-λ蛋白，即野生型犬干扰素CaIFN-λ蛋白的突变体蛋白。其中3种干扰素CaIFN-λ突变体的生物学活性显著优于野生型犬干扰素CaIFN-λ。本发明提供的重组野生型犬干扰素CaIFN-λ蛋白具有优良的抗病毒活性，具有开发成为抗病毒药物和兽医临床应用的巨大潜力和价值。